RT Journal Article
SR Electronic
T1 Uptake in tumor lesions and normal organs using 68Ga-DOTA-TOC receptor PET/CT
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 2094
OP 2094
VO 53
IS supplement 1
A1 Kroiss, Alexander
A1 Putzer, Daniel
A1 Decristoforo, Clemens
A1 Uprimny, Christian
A1 Warwitz, Boris
A1 Gabriel, Michael
A1 Madleitner, Ruth
A1 Waitz, Dietmar
A1 Kendler, Dorota
A1 Virgolini, Irene
YR 2012
UL http://jnm.snmjournals.org/content/53/supplement_1/2094.abstract
AB 2094 Objectives 1) to establish the range of 68GA-DOTA-TOC uptake in liver and bone metastases of patients with neuroendocrine tumors (NETs); 2) the range of its uptake in pancreatic NETs 3) to differentiate between physiological uptake and tumor related somatostatin (SST) related expression in the uncinate processus of the pancreas 4) the physiologic distribution of the radiolabeled somatostatin analog 68Ga-DOTA-TOC. Methods 360 68Ga-DOTA-TOC PET/CT studies in 238 patients were performed since 12/2009. Indications for PET/CT scan were suspected SST-expressing malignancy (N.=53), gastroenteropancreatic NETs (N.=175), non-gastroenteropancreatic NETs (N.=44), NETs of unknown origin (N.=52), other NETs (N.=18) and radioiodine negative metastatic thyroid carcinoma (N.=21). Maximum standardized uptake values (SUVmax) of 68Ga-DOTA-TOC were determined in tumor lesions (liver, bone and pancreas) and normal organs. Results SUVmax was 30.4 +/- 16.8 (N. =135) in liver metastases, 21.0 +/- 19.7 (N. =78) in bone metastases and 36.7 +/- 17.6 (N. =35) in pancreatic neuroeNETs. Target to non target (T/NT) ratios were 2.8 +/- 1.5 for liver metastases, 11.3 +/- 15.1 for bone metastases and 6.1 +/-3.1 in pancreatic NETs. SUVmax of normal organs were determined in: pituitary gland: 8.0 +/- 3.5, thyroid: 4.9 +/- 1.9, lung: 1.6 +/- 0.6, liver: 12.4 +/- 4.0, spleen: 32.9 +/-11.7, adrenal: 16.4 +/- 5.7, kidney: 20.4 +/- 7.6, gastrointestinal tract: 4.7 +/- 1.9, gluteal muscle: 2.3 +/- 0.9, blood pool: 3.6 +/- 1.4, femur: 1.8 +/- 0.8, spine (L5/S1): 2.6 +/- 1.3, pancreas body: 6.5 +/- 2.5 and uncinate processus of the pancreas: 10.5 +/- 4.0 and 35.3 +/- 15.1 (T/NT 5.4 +/- 2.6) in tumors of the uncinate processus (N.=24), respectively. Conclusions 68Ga-DOTA-TOC is an excellent tracer for imaging of tumors with SST receptor expression on the tumor cell surface, facilitating the detection of even small tumor lesions and allowing for a more accurate understanding of the underlying tumor disease due to the high target to non-target ratios